Skip to content
Menu

Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $100

Benzinga Newsdesk 10 hours ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $85 to $100.

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $85 to $100.

Read at benzinga.com